PillRx only · Injection, Solution · Subcutaneous
Ustekinumab
Brands: Stelara · Yesintek · Ustekinumab
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US7 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
ATC—
RxCUI (US)—
US makers2 labelers
Packages11
DEA / ScheduleNone
US acquisition costNADAC · per unit
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$20876.199
Latest avg · Jul 22, 2026
-26%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
17K
Rx · 2026 Q1
16K
Units dispensed
-43%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Janssen Biotech, Inc. | unknown | 8 | SUPPLYING |
| Biocon Biologics Inc. | unknown | 3 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.